Eli Lilly to Buy 3 Vaccine Developers
The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr virus and other pathogens.
Eli Lilly and Company has announced plans to acquire three biotechnology firms focused on vaccine development. The pharmaceutical giant intends to invest up to $4 billion in these acquisitions. The companies are reportedly working on vaccines targeting conditions such as shingles and the Epstein-Barr virus. This move signals a significant expansion of Lilly's vaccine research and development portfolio.
This acquisition highlights Eli Lilly's strategic investment in preventative medicine and its ambition to broaden its therapeutic offerings beyond its current focus areas.
📌 Kaynak
Bu özet NYT Science kaynağından otomatik derlenmiştir. Tamamı için orijinal habere gidin.
Orijinal haberi oku →